{"id":62406,"date":"2025-12-25T01:05:53","date_gmt":"2025-12-25T00:05:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/"},"modified":"2025-12-25T01:05:53","modified_gmt":"2025-12-25T00:05:53","slug":"mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/","title":{"rendered":"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms"},"content":{"rendered":"<div>\n<p>TORONTO&#8211;(BUSINESS WIRE)&#8211;Mountain Valley MD Holdings Inc. (the \u201cCompany\u201d or \u201cMVMD\u201d) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/5\/MVMD_Logo_PR_%281%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/5\/MVMD_Logo_PR_%281%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/21\/MVMD_Logo_PR_%281%29.jpg\"><\/a><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\n<b>Nutraceuticals<\/b> \u2013 Innovations through the Company\u2019s Quicksome\u2122 technology, designed to improve the administration and efficacy of nutraceutical health and wellness products;<\/li>\n<li>\n<b>Agriculture<\/b> \u2013 The Company\u2019s licensed Agrarius agricultural plant signaling technology, designed to organically drive increased crop yields, reduce fertilizer and pesticide usage where desired, and enhance plant health; and<\/li>\n<li>\n<b>Husbandry Animals and Aquatic Species<\/b> \u2013 The application of solubilized drug formulations through the Company\u2019s Quicksol\u2122 technology, designed to positively impact the health of husbandry animals and aquatic species.<\/li>\n<\/ol>\n<p>\n\u201cThroughout 2025, we have remained focused on disciplined execution across each of our business lines,\u201d said Dennis Hancock, President and CEO of Mountain Valley MD. \u201cWe believe the progress we have made in product development, field validation, and commercial foundations positions the Company for the next phase of measured growth.\u201d<\/p>\n<p>\n<b>NUTRACEUTICALS<\/b><\/p>\n<p>\n<b>Quicksome\u2122 Technology, Commercialization, and Business Development Progress<\/b><\/p>\n<p>\nMVMD\u2019s patented liposomal Quicksome\u2122 technology uses proprietary formulations and stabilizing agents to encapsulate active ingredients with the goal of optimizing molecule delivery in sublingual nutraceutical applications. The Company\u2019s Quicksome\u2122 platform continues to focus on delivering molecules where enhanced efficacy, precise dosing, reduced variability, and dose sparing are valued.<\/p>\n<p>\n\u201cOur Quicksome\u2122 technology continues to demonstrate to us its adaptability across multiple product formulations,\u201d Mr. Hancock noted. \u201cWe believe the platform\u2019s delivery characteristics and dose-sparing potential remain compelling for partners seeking differentiated products in competitive wellness categories.\u201d<\/p>\n<p>\nMVMD continues to advance its nutraceutical strategy through its exclusive manufacturing and licensing arrangement with a U.S.-based GMP production partner (the \u201cLead Manufacturer\u201d), which maintains GMP and OTC drug manufacturing capabilities and has installed proprietary equipment to support Quicksome\u2122 sublingual and dermal formulations.<\/p>\n<p>\nThe Lead Manufacturer continues to work with the Company to support production obligations under MVMD\u2019s license agreement with Circadian Wellness Corp. (\u201cCircadian\u201d), as well as MVMD\u2019s proprietary \u201cMountains Of\u2026\u201d product line and other business development initiatives. During 2025, scaled production and commercial activity continued for Circadian\u2019s \u201cEons Dialed\u201d and \u201cEons Deeper Sleep\u201d sublingual products, both incorporating Quicksome\u2122 technology. Circadian reported continued positive consumer reception and sales volumes of its Quicksome\u2122-based products during the year.<\/p>\n<p>\nIn parallel, MVMD has continued business development initiatives to secure additional nutraceutical licensing partnerships through the development of novel formulation work for new clients in multiple human benefit areas including novel hot flash and night sweat symptoms relief in peri menopausal and post-menopausal women, post-workout muscle recovery, anti-inflammation, and joint health. The Company also remains engaged with a U.S.-based multi-level marketing client for a novel fenugreek glycosides testosterone formulation utilizing Quicksome\u2122 quick-dissolve tablet technology. The formulation has supported documented performance in male subjects, and iterative product evaluations related to taste and dissolution have continued, with commercial discussions expected to advance as partner review processes progress. Additional client discussions have taken place in the fourth quarter and the Company expects the launch of a fenugreek glycosides testosterone formulation through a licensee in the first half of 2026.<\/p>\n<p>\nThe Company\u2019s \u201cMountains Of\u2026\u201d proprietary brand continues to hold U.S. trademark protection across multiple product categories, including Sleep, Energy, Relief, Libido, and Lean, to support ongoing GMP sample development and business development activities. Distribution partners may elect to market MVMD\u2019s branded products or pursue proprietary white-label versions under their own brands.<\/p>\n<p>\n<b>AGRICULTURE<\/b><\/p>\n<p>\n<b>Agrarius Business Development and Commercialization Progress<\/b><\/p>\n<p>\n\u201cWe believe the continued validation of Agrarius across diverse crops and geographies reinforces its potential role in sustainable agricultural practices,\u201d said Mr. Hancock. \u201cOur focus remains on building a strong, data-driven foundation to support long-term commercial adoption.\u201d<\/p>\n<p>\nMVMD continues to advance commercialization in its agricultural division, which is focused on the licensed distribution of the Agrarius\u2122 plant signaling technology. Under its exclusive license agreement with Agrarius Corp. (\u201cAC\u201d), MVMD holds the exclusive rights to sell the Agrarius product throughout North America, Central America, South America, and the Caribbean (the \u201cExclusive Territory\u201d).<\/p>\n<p>\nThe Agrarius product is mixed with water or other agricultural inputs at the point of application and applied via sprayer at targeted stages of a plant\u2019s lifecycle. Agrarius has been tested across numerous crops and has demonstrated its ability to naturally increase yields, improve plant resilience, and support reduced fertilizer usage, with results varying by crop and environment.<\/p>\n<p>\n<b>Brazil Citrus Trials, Including Positive Younger Tree Results<\/b><\/p>\n<p>\nMVMD has been working with a client-directed third-party agricultural partner, FARMATAC, in Brazil to assess the impact of the application of the Agrarius product on both mature and young citrus orchards. FARMATAC has extensive experience designing and managing advanced citrus trials and has completed the contracted evaluations in commercial citrus orchards.<\/p>\n<p>\nThe Company previously reported the following results from mature Hamlin and Valencia orange trees:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nHamlin Variety: Agrarius-treated orchards demonstrated improved plant condition and a productivity increase of approximately 15% per hectare. Juice yield analysis showed that the treated oranges required 20 fewer boxes to produce one ton of juice compared to the control, resulting in an approximate total yield increase of 22%. Independent agronomists also observed a visual reduction in symptoms associated with Huanglongbing (HLB), also known as citrus greening disease.<\/li>\n<li>\nValencia Variety: The Agrarius-treated block achieved a 49% average yield increase. Treated trees also exhibited stronger vigor and canopy density, consistent with improved nutrient uptake and photosynthetic activity.<\/li>\n<\/ul>\n<p>\nBuilding on the mature orchard results, newly completed trials on additional citrus blocks, including younger orchards and additional varietals at the client\u2019s site, have now demonstrated further compelling outcomes. In trials that included treatments on younger trees, Agrarius-treated areas showed materially stronger plant vigor, improved flowering and fruit set, enhanced resilience to stress, including during periods of drier growing conditions, and significantly higher productivity when compared to control blocks. Notably, productivity gains of greater than 50 percent were recorded in Pera varietals, alongside results consistent with prior Hamlin and Valencia performance, reinforcing the potential lifecycle impact of Agrarius when applied earlier in orchard development and its potential role in helping mitigate yield variability under increasingly challenging climatic conditions.<\/p>\n<p>\n\u201cThe Brazil citrus trial demonstrates to us that Agrarius\u2122, under real farm conditions and third-party monitoring, delivered substantial yield improvements, stronger plant health, and meaningful mitigation of Greening stress in citrus,\u201d continued Hancock. \u201cOur agronomy team recently reviewed the trial results with the client\u2019s leadership team and it is believed the findings will support commercial expansion in 2026, positioning Agrarius as a high-impact, low-disruption tool for Brazilian citriculture.\u201d<\/p>\n<p>\nThe Company believes that the continued observation of reduced visible HLB symptoms across its Brazil citrus programs, including in younger orchards, represents one of the most meaningful indicators emerging from its citrus field work to date. These results are consistent with citrus trials previously reported by the Company and support the potential lifecycle relevance of Agrarius in orchards impacted by citrus greening disease.<\/p>\n<p>\n\u201cHLB has fundamentally altered citrus production in many regions, and producers still face the reality that there is no known cure,\u201d said Hancock. \u201cSeeing similar trends not only in mature trees but also in younger orchards strengthens our view that, if sustained, Agrarius could become an important organic tool to help growers manage greening pressure while building healthier, more productive orchards over time.\u201d<\/p>\n<p>\n<b>Broad Crop Validation and LATAM Expansion<\/b><\/p>\n<p>\nIn addition to citrus, Agrarius trials conducted during the year across key crops in Brazil and Colombia in partnership with universities, private agronomy labs, and farmer networks continued to demonstrate to the Company positive outcomes, including:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCorn \u2013 Yield gains of approximately 14.8 percent and 11.2 percent in UNESP trials, associated with improved chlorophyll concentration and root development.<\/li>\n<li>\nSugarcane \u2013 Yield improvements of 8 to 12 tons per hectare, increased sugar content, and reduced pest damage in Agroquatro trials, alongside improved early development in seedling clone studies.<\/li>\n<li>\nSoybeans \u2013 Average yield gains of 6.34 sacs per hectare across 14 farmer validations, with high-performance producers achieving gains exceeding 15 percent.<\/li>\n<li>\nCotton \u2013 Increases in bolls per plant and overall yield supported by improved photosynthetic efficiency.<\/li>\n<li>\nPotatoes \u2013 Productivity increases of approximately 18.5 percent in summer harvest trials.<\/li>\n<\/ul>\n<p>\nOf particular note, during extended dry periods observed in Brazil field programs, Agrarius-treated crops experienced notably lower yield losses than untreated controls, supporting the product\u2019s potential to improve water-use efficiency and maintain productivity under drought stress as part of an integrated agronomic program.<\/p>\n<p>\n\u201cThe recent citrus trialing activity has produced results that reinforce what we are seeing across multiple crops in Brazil, that Agrarius is not only driving yield improvement, but also helping plants stay productive when conditions are less than ideal,\u201d continued Hancock. \u201cIn markets where growers face increasing climate variability, this kind of resilience can be just as important as top-line yield gains.\u201d<\/p>\n<p>\nIn Colombia, MVMD is completing its large-scale pasture grass productivity program in partnership with FEDEGAN, the national cattle growers\u2019 federation representing approximately 43 million hectares of pastureland, and the National University of Colombia, with preliminary results demonstrating improved vegetation health, faster regrowth, and enhanced pasture quality, supported by satellite analysis and laboratory validation. Final results are expected in the first quarter of 2026.<\/p>\n<p>\n<b>HUSBANDRY ANIMALS \/ AQUATIC SPECIES<\/b><\/p>\n<p>\n<b>Soluvec\u2122 1% Commercialization Update and Strategic Review<\/b><\/p>\n<p>\nMVMD has applied its patented Quicksol\u2122 solubilization technology to ivermectin to create its Soluvec\u2122 1% formulation, which was designed to provide a safer and more effective solution for administration across husbandry animals and aquatic species. The Soluvec\u2122 1% formulation has demonstrated nine-month stability at room and refrigerated temperatures through third-party validation and remains the Company\u2019s primary Quicksol\u2122-based commercial asset.<\/p>\n<p>\nThe Company\u2019s commercialization strategy for Soluvec\u2122 1% has been to advance the technology through third-party licensing. In Bangladesh, MVMD entered into an exclusive license agreement with an arm\u2019s length, privately held partner to manufacture and distribute Soluvec\u2122 1% products in injectable and feed coating formats, in return for royalty payments based on net sales. As previously disclosed, the licensee has produced approximately 200 tonnes of Soluvec\u2122 1% coated fish feed and distributed product through local channels.<\/p>\n<p>\nWhile this activity represented an important first step in demonstrating large-scale manufacturing and application of the Soluvec\u2122 formulation, royalty revenues and overall commercial traction during 2025 have remained below management\u2019s expectations. External market disruption, including impacts from Cyclone Remal in 2024, has affected industry conditions in the region, and MVMD continues to assess the most effective pathway to advance broader adoption of the technology.<\/p>\n<p>\n\u201cWe continue to believe in the strength of the underlying science and formulation behind Soluvec\u2122,\u201d stated Hancock. \u201cAt the same time, we recognize that realizing its commercial potential requires partners with the right operational scale, market reach, and strategic alignment.\u201d<\/p>\n<p>\nAs part of its assessment, the Company is undertaking a strategic review of its Soluvec\u2122 1% licensing structure, including evaluating options to modify or restructure territorial exclusivity in Bangladesh, subject to contractual rights and ongoing discussions between relevant parties. The objective is to ensure MVMD has the flexibility to work with partners best positioned to drive effective commercialization.<\/p>\n<p>\nWith a continued focus on disciplined capital allocation, MVMD intends to prioritize low-capital, royalty-based licensing opportunities for Soluvec\u2122 1% rather than direct investment in manufacturing or market buildout. In this context, management has initiated discussions with potential new licensees in Latin America, where demand for scalable and cost-effective husbandry and aquaculture health solutions remains significant and where the Company\u2019s patent strategy supports future commercial development.<\/p>\n<p>\nGlobal interest in Soluvec\u2122 continues in management\u2019s view, supported by the Company\u2019s peer-reviewed data demonstrating improved bioavailability, efficacy, and stability relative to conventional ivermectin formulations. While the Company does not anticipate near-term material revenues until additional licensing arrangements are secured, MVMD believes that a more selective and partner-aligned approach can better position Soluvec\u2122 for sustainable royalty growth over time.<\/p>\n<p>\n\u201cSoluvec\u2122 remains an important asset for the Company, and we are working to align it with partners who can advance this opportunity effectively as we move into 2026,\u201d Hancock added.<\/p>\n<p>\n<b>ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.<br \/>\n<br \/><\/b>Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\npatented Quicksome\u2122 oral formulation and delivery technologies,<\/li>\n<li>\npatented Quicksol\u2122 solubility formulation technology<\/li>\n<li>\nlicensed product reseller of Agrarius\u2122, a novel agricultural plant signaling technology<\/li>\n<\/ul>\n<p>\nConsistent with its vision towards \u201cMore Life\u201d, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD\u2019s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.<\/p>\n<p>\nMVMD\u2019s patented Quicksome\u2122 technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.<\/p>\n<p>\nMVMD\u2019s patented Quicksol\u2122 technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.<\/p>\n<p>\nMVMD\u2019s licensed Agrarius\u2122 agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.<\/p>\n<p>\nFor more Company information and contact details, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mvmd.com%2F&amp;esheet=54384335&amp;newsitemid=20251224207390&amp;lan=en-US&amp;anchor=www.MVMD.com&amp;index=1&amp;md5=cf35aa1aeccb2def6e71948f2dbc6f15\" rel=\"nofollow\" shape=\"rect\">www.MVMD.com<\/a>.<\/p>\n<p>\n<b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION<\/b><\/p>\n<p>\nCertain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as &#8220;anticipate&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;intend&#8221;, &#8220;should&#8221;, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.<\/p>\n<p>\nThe Company&#8217;s actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.<\/p>\n<p>\nThe Company is making forward-looking statements, including but not limited to: the continued advancement of the Company\u2019s lines of business; anticipated license arrangements and launches and the timing thereof with regard to the Company\u2019s Quicksome\u2122 technology; continued trials and anticipated results of the Company\u2019s licensed Agrarius\u2122 product and the timing thereof; and the securing of additional licensing arrangements, and the structure and timing thereof, regarding the Company\u2019s Soluvec\u2122 product.<\/p>\n<p>\nThe Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company&#8217;s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.<\/p>\n<p>\nNeither the CSE nor OTC has reviewed or approved the contents of this press release.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nDennis Hancock<br \/>\n<br \/>President and Chief Executive Officer<br \/>\n<br \/>Mountain Valley MD Holdings Inc.<br \/>\n<br \/>Investor Relations @ 647-725-9755<br \/>\n<br \/>Email: <a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#105;&#110;&#x66;&#x6f;&#64;m&#118;&#109;&#x64;&#x2e;co&#109;\" rel=\"nofollow\" shape=\"rect\">&#x69;&#x6e;&#x66;&#x6f;&#x40;&#x6d;&#x76;&#x6d;&#100;&#46;&#99;&#111;&#109;<\/a><br \/><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mvmd.com%2F&amp;esheet=54384335&amp;newsitemid=20251224207390&amp;lan=en-US&amp;anchor=www.MVMD.com&amp;index=2&amp;md5=1d5c3501011cc4b9d70e4b82ba639f42\" rel=\"nofollow\" shape=\"rect\">www.MVMD.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO&#8211;(BUSINESS WIRE)&#8211;Mountain Valley MD Holdings Inc. (the \u201cCompany\u201d or \u201cMVMD\u201d) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus: Nutraceuticals \u2013 Innovations through the Company\u2019s Quicksome\u2122 technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture \u2013 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62406","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO&#8211;(BUSINESS WIRE)&#8211;Mountain Valley MD Holdings Inc. (the \u201cCompany\u201d or \u201cMVMD\u201d) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus: Nutraceuticals \u2013 Innovations through the Company\u2019s Quicksome\u2122 technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture \u2013 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-25T00:05:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms\",\"datePublished\":\"2025-12-25T00:05:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/\"},\"wordCount\":2529,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251224207390\\\/en\\\/1865004\\\/22\\\/MVMD_Logo_PR_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/\",\"name\":\"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251224207390\\\/en\\\/1865004\\\/22\\\/MVMD_Logo_PR_%281%29.jpg\",\"datePublished\":\"2025-12-25T00:05:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251224207390\\\/en\\\/1865004\\\/22\\\/MVMD_Logo_PR_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251224207390\\\/en\\\/1865004\\\/22\\\/MVMD_Logo_PR_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/","og_locale":"en_US","og_type":"article","og_title":"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms - Pharma Trend","og_description":"TORONTO&#8211;(BUSINESS WIRE)&#8211;Mountain Valley MD Holdings Inc. (the \u201cCompany\u201d or \u201cMVMD\u201d) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP) provides a year-end business update on its commercialization progress across its three core areas of focus: Nutraceuticals \u2013 Innovations through the Company\u2019s Quicksome\u2122 technology, designed to improve the administration and efficacy of nutraceutical health and wellness products; Agriculture \u2013 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-25T00:05:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms","datePublished":"2025-12-25T00:05:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/"},"wordCount":2529,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/","url":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/","name":"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg","datePublished":"2025-12-25T00:05:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251224207390\/en\/1865004\/22\/MVMD_Logo_PR_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mountain-valley-md-provides-year-end-business-update-advances-commercialization-across-core-platforms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Mountain Valley MD Provides Year-End Business Update, Advances Commercialization Across Core Platforms"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62406"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62406\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}